Brokers Set Expectations for Hologic, Inc.’s FY2018 Earnings (HOLX)
Hologic, Inc. (NASDAQ:HOLX) – Equities research analysts at Leerink Swann reduced their FY2018 earnings estimates for Hologic in a research note issued on Thursday. Leerink Swann analyst R. Newitter now expects that the medical equipment provider will earn $2.15 per share for the year, down from their previous estimate of $2.17. Leerink Swann also issued estimates for Hologic’s FY2019 earnings at $2.38 EPS and FY2020 earnings at $2.65 EPS.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. During the same quarter last year, the company posted $0.51 EPS. The firm’s revenue was up 12.4% compared to the same quarter last year. COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2017/10/15/brokers-set-expectations-for-hologic-inc-s-fy2018-earnings-holx.html.
HOLX has been the topic of a number of other reports. Needham & Company LLC reiterated a “buy” rating and set a $50.00 price objective on shares of Hologic in a research note on Monday, October 2nd. Zacks Investment Research downgraded shares of Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Deutsche Bank AG reduced their price objective on shares of Hologic from $51.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday, August 3rd. Royal Bank of Canada reduced their price objective on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research note on Thursday, August 3rd. Finally, Barclays PLC reduced their price objective on shares of Hologic from $53.00 to $51.00 and set an “overweight” rating on the stock in a research note on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $47.77.
Hologic (NASDAQ HOLX) opened at 36.28 on Friday. Hologic has a 12 month low of $35.15 and a 12 month high of $46.80. The firm has a 50-day moving average of $37.64 and a 200 day moving average of $41.89. The stock has a market cap of $10.18 billion, a PE ratio of 13.51 and a beta of 0.91.
In other news, Director Lawrence M. Levy sold 9,596 shares of Hologic stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $36.81, for a total value of $353,228.76. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Karleen Marie Oberton sold 4,704 shares of Hologic stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $45.19, for a total transaction of $212,573.76. The disclosure for this sale can be found here. In the last three months, insiders have sold 35,479 shares of company stock worth $1,388,236. 0.79% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in HOLX. Capital World Investors acquired a new position in shares of Hologic in the 2nd quarter worth approximately $312,441,000. HealthCor Management L.P. acquired a new position in shares of Hologic in the 2nd quarter worth approximately $76,604,000. Columbus Circle Investors acquired a new position in shares of Hologic in the 2nd quarter worth approximately $54,511,000. Vanguard Group Inc. grew its stake in shares of Hologic by 4.2% in the 2nd quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock worth $1,340,850,000 after purchasing an additional 1,200,825 shares during the last quarter. Finally, Koch Industries Inc. grew its stake in shares of Hologic by 15,554.1% in the 2nd quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock worth $1,125,000 after purchasing an additional 1,142,138 shares during the last quarter. 96.38% of the stock is currently owned by institutional investors.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.